Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
The cash-strapped biotech has begun generating its first revenue from over-the-counter cosmetic treatments, as it pivots away from its original oncology drugs Key Takeaways: Kintor Pharma is shifting from its…
Kintor Pharma eyes regeneration with over-the-counter cosmetic treatments
The Suzhou-based drug developer said it will commercialize its hair-loss product despite disappointing clinical testing results, as it shifts away from cancer drugs Key Takeaways: Kintor announced it will commercialize…
RELATED ARTICLES
-
Plenty of room for growth in China’s hair transplant market
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
